OncoPep

FDA
Pharma

FDA revokes approval of Oncopeptides' Pepaxto

Following an FDA request for withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. market in late 2022, the other shoe has dropped.
Fraiser Kansteiner Feb 23, 2024 11:10am
Food and Drug Administration

FDA wants to pull back authorization of Oncopeptides' Pepaxto

Dec 8, 2022 8:10am
Jakob Lindberg

Oncopeptides says trial data good, but not enough to sway FDA

Oct 28, 2022 7:24am
FDA

FDA adcomm rejects Oncopeptides' multiple myeloma drug Pepaxto

Sep 23, 2022 11:40am
FDA

FDA oncology nods will be challenging for Spectrum, Oncopeptides

Sep 21, 2022 8:45am
FDA Building

FDA puts the microscope on 2 more cancer approvals

Jul 22, 2022 11:12am